Search

Background: Ganoderma lucidum (G. lucidum) is one of the most popular edible mushrooms in the world which has various pharmacological components. Recently, some animal studies have investigated the lipid-lowering effects of G. lucidum and have shown contradictory results. This study aims to systematically review the effects of G. lucidum on lipid parameters in animal studies. Materials and Methods: A systematic search was conducted in the Medline database (PubMed), Scopus, Web of Science, Cochrane Library, and Google Scholar up to the end of January 2022. Only animal studies and all eligible randomized controlled trials (RCTs), including cluster RCTs and randomized crossover trials were included. The English language studies that assessed the effects of G. lucidum on lipid profiles including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and very low-density lipoproteins (VLDL) were selected. Results: Among 358 studies, 49 articles were included in the systematic review and meta-analysis. G. lucidum consumption was associated with decreased levels of TG (standardized mean difference [SMD] = -1.52, 95% CI: -1.79, -1.24), TC (SMD = -1.51, 95% CI: -1.75, -1.27), LDL-C (SMD = -2.03, 95% CI: -2.37, -1.69) and VLDL (SMD =-1.06, 95% CI: -1.638, -0.482). Furthermore, G. lucidum consumption was associated with increased levels of HDL-C (SMD = 1.03, 95% CI: 0.73, 1.33). Conclusion: G. lucidum has favorable effects on TG, TC, LDL-C, HDL-C, and VLDL. Different doses of G. lucidum have various degrees of effectiveness on lipid profiles. [ABSTRACT FROM AUTHOR]